<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">02/21/23</p><p class="summary"><strong> <em>Summary: New data in 9 studies; Expedited timeline in 19 studies; 15 new studies.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>ALX Oncology</td>
    <td>ALX Oncology Announces First Patient Dosed in ASPEN-07 a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05524545" target="_blank">ASPEN-07 (NCT05524545)</a></td><td><select class="form-select" id="select_form_1" name="NCT05524545"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>ARX517</td>
    <td>ARX517 Ambrxs Proprietary Anti-PSMA ADC Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04662580" target="_blank">APEX-01 (NCT04662580)</a></td><td><select class="form-select" id="select_form_2" name="NCT04662580"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Bellicum</td>
    <td>Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02744287" target="_blank">NCT02744287</a></td><td><select class="form-select" id="select_form_3" name="NCT02744287"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>LAVA Therapeutics</td>
    <td>LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05369000" target="_blank">NCT05369000</a></td><td><select class="form-select" id="select_form_4" name="NCT05369000"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Aura Biosciences</td>
    <td>Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04417530" target="_blank">NCT04417530</a></td><td><select class="form-select" id="select_form_5" name="NCT04417530"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Junshi Biosciences</td>
    <td>Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04085276" target="_blank">TORCHLIGHT (NCT04085276)</a></td><td><select class="form-select" id="select_form_6" name="NCT04085276"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Telix</td>
    <td>Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03849118" target="_blank">ZIRCON (NCT03849118)</a></td><td><select class="form-select" id="select_form_7" name="NCT03849118"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Actinium</td>
    <td>Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02665065" target="_blank">SIERRA (NCT02665065)</a></td><td><select class="form-select" id="select_form_8" name="NCT02665065"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>BerGenBio</td>
    <td>BerGenBio's Anti-AXL/PD-1 Combo Trial Boosts Confidence About Activity in SKT11-Mutated NSCLC</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03184571" target="_blank">NCT03184571</a></td><td><select class="form-select" id="select_form_9" name="NCT03184571"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Blue Earth Diagnostics</td>
    <td>Blue Earth Diagnostics Produces New Data Supporting FDA Approval of Prostate Cancer Imaging Agent</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04186819" target="_blank">LIGHTHOUSE (NCT04186819)</a></td><td><select class="form-select" id="select_form_10" name="NCT04186819"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle">    <td>Medivir</td>
    <td>Medivir completes initial Phase Ib part of HCC therapy trial</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_11" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>NSCLC with a KRAS mutation</td>
    <td>Navire Pharma Inc. a BridgeBio company</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td><p>BBP-398 with nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_500">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05375084" target="_blank">NCT05375084</a></td><td><select class="form-select" id="select_form_12" name="NCT05375084"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced solid tumors</td>
    <td>Kineta Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td><p>KVA12123 - Dose Escalation; KVA12123 Plus Pembrolizumab - Dose Escalation; KVA12123 - Dose Expansion; KVA12123 Plus Pembrolizumab - Dose Expansion</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_501">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05708950" target="_blank">NCT05708950</a></td><td><select class="form-select" id="select_form_13" name="NCT05708950"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Advanced melanoma or non-small cell lung cancer</td>
    <td>iOx Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td><p>IMM60; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_502">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05709821" target="_blank">NCT05709821</a></td><td><select class="form-select" id="select_form_14" name="NCT05709821"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Solid tumors with mutated KRAS/NRAS</td>
    <td>Elicio Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>ELI-002 7P</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05726864" target="_blank">NCT05726864</a></td><td><select class="form-select" id="select_form_15" name="NCT05726864"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Recurrent Extensive Stage Small Cell Lung Carcinoma</td>
    <td>Shanghai Yidian Pharmaceutical Technology Development Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td><p>HTMC0435; Temozolomide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05728619" target="_blank">NCT05728619</a></td><td><select class="form-select" id="select_form_16" name="NCT05728619"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Extensive-stage small cell lung cancer</td>
    <td>Biocity Biopharmaceutics Co. Ltd.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td>SC0245; Irinotecan</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05731518" target="_blank">NCT05731518</a></td><td><select class="form-select" id="select_form_17" name="NCT05731518"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>NSCLC</td>
    <td>St. Joseph's Healthcare Hamilton</td>
<td><p>Not Applicable</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>Medtronic Signia Stapler; Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05727735" target="_blank">NCT05727735</a></td><td><select class="form-select" id="select_form_18" name="NCT05727735"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Malignant mesothelioma</td>
    <td>Brigham and Women's Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td><p>Magnesium sulfate; Normal Saline</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_507">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05730816" target="_blank">NCT05730816</a></td><td><select class="form-select" id="select_form_19" name="NCT05730816"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Pain in patients with bone metastases from lung cancer</td>
    <td>The Third Affiliated hospital of Zhejiang Chinese Medical University</td>
<td><p>Not Applicable</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td>Transcutaneous electrical acupoint stimulation; Sham transcutaneous electrical acupoint stimulation; Routine palliative treatment</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05730972" target="_blank">NCT05730972</a></td><td><select class="form-select" id="select_form_20" name="NCT05730972"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced solid tumors</td>
    <td>Northwestern University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>Biospecimen Collection; Computed Tomography; Devimistat; Fluorouracil; Gemcitabine Hydrochloride; Hydroxychloroquine; Magnetic Resonance Imaging</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05733000" target="_blank">NCT05733000</a></td><td><select class="form-select" id="select_form_21" name="NCT05733000"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Level 1 oral capsules administered in combination with nivolumab|Level 2 oral capsules administered in combination with nivolumab|Level 3 oral capsules administered in combination with nivolumab|RP2D defined dose. Oral capsules administered in combination with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BBP-398 with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1a Dose Escalation: Assess safety tolerability and recommended phase 2 dose (RP2D) of BBP-398 in combination with nivolumab|Phase 1b Dose Expansion: Assess antitumor activity of BBP-398 in combination with nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Anti-tumor activity will be defined by objective response rate (ORR) according to RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Completion of 1 Cycle (28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: KVA12123 Plus Pembrolizumab - Dose Expansion; Drug: KVA12123 Plus Pembrolizumab - Dose Escalation; Drug: KVA12123 - Dose Escalation; Drug: KVA12123 - Dose Expansion</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse Events|AEs related to study drug|Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).; Type and frequency of adverse events as assessed by CTCAE v4.0.; Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3 dose levels of IMM60 will be assessed (1 3 and 9 mg/m^2 administered IV every 3 weeks for up to 6 cycles)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.|Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after to determine any changes in PD-L1 expression. After this one cycle the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.|IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: IMM60; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1 Co-Primary Objective - Identify Maximum Tolerated Dose (MTD)|Phase 1 Co-Primary Objective - Safety|Phase 2 Primary Objective - Progression-free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To characterize the safety of IMM60 alone and in combination with pembrolizumab as assessed by the frequency of Grade 3 or higher treatment-related adverse events; To compare the progression-free survival (PFS) rate at 12 months in the randomized arms comparing pembrolizumab alone versus IMM60 + pembrolizumab in patients with advanced PD-L1 ≥50% NSCLC; To confirm the maximum tolerated dose (MTD) of IMM60 alone and in combination with pembrolizumab defined as the highest dose level at which 2 out of 6 participants experience a dose-limiting toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through Phase 1 completion an average of 1 year; 12 months after last participant enrolled; Assessed at the end of Cycle 1 for each patient (each Cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ELI-002 7P</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Evaluate the safety of ELI-002 7P|Phase 2: Determine whether ELI-002 7P improves relapse-free survival (RFS) compared with Observation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>RFS is assessed by the central imaging laboratory through computed tomography (CT) imaging or magnetic resonance imaging (MRI) with contrast and using iRECIST criteria; Safety will be assessed by the incidence of adverse events (AEs) and clinically significant changes in laboratory tests and vital signs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After the last radiographic assessment at Visit 23 (Week 106); 28 days after the first dose of ELI-002 7P</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Escalating doses of HTMC0435 and Temozolomide|Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Temozolomide; Drug: HTMC0435</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting toxicities (DLT) of HTMC0435 combined with Temozolomide|Adverse events (AE) of HTMC0435 combined with Temozolomide|Maximum tolerable dose (MTD) and RP2D of HTMC0435 combined with Temozolomide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 Day 1 to Cycle 1 Day 21; Through study completion an average of 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SC0245 and irinotecan combination are administered one cycle that is consisted of 28 days until disease progression or death or loss of follow-up or withdrawal.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Irinotecan; Drug: SC0245</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 (phase 1 dose escalation):Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SC0245 and irinotecan|Part 2 (phase 1 dose expansion):Safety and tolerability in terms of adverse events|Part 3(phase 2 combination therapy):Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs electrocardiograms (ECGs) safety and laboratory parameters.; MTD Will be defined as the highest dose level at which = 30% patients experience dose limiting toxicity. Dose-limiting toxicity as described in the protocol that is not related to disease progression intercurrent illness or concomitant medications and that despite optional therapeutic intervention meets protocol-defined criteria. The RP2D will be determined based on MTD and the feasibility of the administration.; Defined as the percentage of participants having a CR or PR based on investigator assessment per RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the first dose of study treatment until 30 days after the last dose up to approximately 24 months; Up to 24 months.; Up to 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients randomized to this arm will undergo RTS segmentectomy with the Medtronic Signia Stapler.|Patients randomized to this arm will undergo RTS segmentectomy with the Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling; Device: Medtronic Signia Stapler</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Feasibility and safety|Recruitment|Randomization|Data collection of stapler reload model|Data collection of stapler quantities|Data collection of energy sealing data|Data collection of energy device data</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Ability to collect the type of stapler reloads used; No adverse impacts of the study procedures on participants; Ability to collect the generator setting of the energy device; Ability to randomize patients to one of two groups; Recruitment rate of at least 70%; Ability to collect the number of stapler reloads used; Ability to collect the sealing time in seconds</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 weeks post-surgery; Up to 8 weeks after recruitment first opens; Baseline</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).|Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Normal Saline; Drug: Magnesium sulfate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>AUC of SCr measured daily over 7 days in Mg- versus placebo-treated patients|Composite Global Rank</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint is the area under the curve (AUC) of SCr measured daily over 7 days in Mg- versus placebo-treated patients; As a co-primary endpoint investigators will construct a composite global rank endpoint in which the highest rank is assigned to those who die within 7 days the second highest rank is assigned to those who survive but require RRT within 7 days and all others ranked according to their SCr AUC since RRT and death are important competing risks.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>7 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Sham Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>A pair of conductive gel patch connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument are respectively affixed to the ipsilateral Jiaji acupoint group (EX-B2) or the ipsilateral limb acupoint group(Hegu (LI4) - Waiguan (TE5) or Zusanli (ST36) - Sanyinjiao (SP6)) so as contralateral side.||A single TEAS treatment takes 30 min. TEAS specific parameters were dilatation wave 2/100 Hz and stimulus current intensity in degrees as tolerated by the patient.||7 days was considered as 1 session. Self-controlled treatment refers to not setting an upper limit on the number of treatment times but must have met at least 3 days or 5 times of TEAS treatment within each session.||A total of 4 sessions of treatment were administered.|Each step of the sham TEAS operation is the same as the TEAS group. A total of 4 sessions of treatment were administered. 10 free TEAS treatments will be given after the trial.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Transcutaneous electrical acupoint stimulation; Drug: Routine palliative treatment; Device: Sham transcutaneous electrical acupoint stimulation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The response rate of average pain in the brief pain inventory (BPI) at the end of week 4</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Subjects in which complete or partial relief of pain was achieved were pain responders; Subjects whose pain progressed or was indeterminate response were non responders. The response rate of average pain = ((CR+PR) / No. of subjects) *100%.; According to the international consensus on palliative radiotherapy endpoints for bone metastasis clinical trials the degree of therapeutic response for bone metastatic pain can be classified as complete response (CR: pain score of 0 and no increase in daily oral morphine equivalent dose (OMED) ) partial response (PR: ①pain score decrease of ≥ 2 and no increase in OMED; ②pain score no increase and decrease of ≥ 25% in OMED) pain progression (PP: ①≥ 2 increase in pain score with no decrease in OMED; ②≥ 1 increase in pain score with ≥ 25% increase in OMED) and indeterminate response (IR: cases not classified as CR / PR / PP).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>week 4</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with colorectal cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.|Patients with pancreatic cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.|Patients with gastroesophageal cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients with urothelial ovarian or non-small cell lung cancer receive devimistat IV gemcitabine IV plus HCQ PO on study. Patients with biliary tumors receive devimistat IV and gemcitabine IV or HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Procedure: Computed Tomography; Drug: Hydroxychloroquine; Drug: Devimistat; Procedure: Biospecimen Collection; Procedure: Magnetic Resonance Imaging</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 in patients with solid tumors treated under this protocol. ORR is defined as the percentage of patients with documented complete response (CR) plus the percentage of patients with documented partial response (PR). ORR will be reported with the corresponding exact confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Time from baseline to disease progression initiates subsequent anti-cancer therapy or 24 months (whichever occurs first)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1892 days; Enrollment decreased by: 76; Trial completed; Primary Completion Date moved earlier by 1912 days</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td><p>Decitabine (DAC); Tetrahydrouridine (THU); Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03233724" target="_blank">NCT03233724</a></td><td><select class="form-select" id="select_form_22" name="NCT03233724"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 288 days; Enrollment decreased by: 33; Primary Completion Date moved earlier by 487 days</strong></td>
    <td>Extensive Stage Lung Small Cell Cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td><p>Atezolizumab; Carboplatin; Entinostat; Etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04631029" target="_blank">NCT04631029</a></td><td><select class="form-select" id="select_form_23" name="NCT04631029"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 154 days; Enrollment decreased by: 69; Trial terminated; Primary Completion Date moved earlier by 348 days</strong></td>
    <td>T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer</td>
    <td>Sihuan Pharmaceutical Holdings Group Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td>XZP-5809-TT1 Tablet</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04622072" target="_blank">NCT04622072</a></td><td><select class="form-select" id="select_form_24" name="NCT04622072"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 365 days; Primary Completion Date moved earlier by 273 days</strong></td>
    <td>Stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer</td>
    <td>University of California San Francisco</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td>Osimertinib; Therapeutic Conventional Surgery</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03433469" target="_blank">NCT03433469</a></td><td><select class="form-select" id="select_form_25" name="NCT03433469"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 130 days; Enrollment decreased by: 185; Trial completed; Primary Completion Date pushed later by 113 days</strong></td>
    <td>Metastatic non-small cell lung cancer microsatellite stable colorectal cancer gastroesophageal adenocarcinoma and metastatic urothelial cancer</td>
    <td>Gritstone bio Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td><p>GRT-C901; GRT-R902; nivolumab; ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03639714" target="_blank">NCT03639714</a></td><td><select class="form-select" id="select_form_26" name="NCT03639714"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Treatment-naive extensive-stage small cell lung cancer</td>
    <td>University of Chicago</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td><p>Ablative Radiation; Durvalumab; Etoposide; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05068232" target="_blank">NCT05068232</a></td><td><select class="form-select" id="select_form_27" name="NCT05068232"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 592 days; Trial terminated</strong></td>
    <td>Autoimmune Diseases</td>
    <td>Alliance Foundation Trials LLC.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td><p>Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03656627" target="_blank">NCT03656627</a></td><td><select class="form-select" id="select_form_28" name="NCT03656627"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 30; Changed status from recruiting to active</strong></td>
    <td>Stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease</td>
    <td>University of Michigan Rogel Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td><p>Pembrolizumab; Pemetrexed; Carboplatin; Rucaparib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03559049" target="_blank">NCT03559049</a></td><td><select class="form-select" id="select_form_29" name="NCT03559049"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 295 days; Trial completed</strong></td>
    <td>Locally Advanced or Metastatic Epithelial Tumor</td>
    <td>Sichuan Baili Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td>SI-B001</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04603287" target="_blank">NCT04603287</a></td><td><select class="form-select" id="select_form_30" name="NCT04603287"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 697 days; Enrollment decreased by: 36; Changed status from not yet recruiting to withdrawn; Start Date moved earlier by 622 days</strong></td>
    <td>EGFR Exon 20 gene mutant stage IV non-small cell lung cancer</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td>Poziotinib Hydrochloride; 1429757-68-5 HM781-36B NOV-1201 Hydrochloride NOV120101 Hydrochloride Poziotinib HCl POZIOTINIB HYDROCHLORIDE</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05045404" target="_blank">NCT05045404</a></td><td><select class="form-select" id="select_form_31" name="NCT05045404"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation</td>
    <td>Daiichi Sankyo Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td>U3-1402 (FL-DP); U3-1402 (CTM-1 Lyo-DP); U3-1402 (CTM-3 Lyo-DP)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03260491" target="_blank">NCT03260491</a></td><td><select class="form-select" id="select_form_32" name="NCT03260491"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>University of Southern California</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td><p>Atezolizumab and Recombinant Human Hyaluronidase; Survey Administration</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_515">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05340309" target="_blank">NCT05340309</a></td><td><select class="form-select" id="select_form_33" name="NCT05340309"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 30; Changed status from recruiting to active</strong></td>
    <td>Stage IIIB or IV non-small cell lung cancer with EGFR mutations</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td>Osimertinib; Radiation Therapy; Therapeutic Conventional Surgery</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03410043" target="_blank">NCT03410043</a></td><td><select class="form-select" id="select_form_34" name="NCT03410043"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 36; Changed status from recruiting to active</strong></td>
    <td>Non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent)</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td>Poziotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03066206" target="_blank">NCT03066206</a></td><td><select class="form-select" id="select_form_35" name="NCT03066206"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 143; Changed status from recruiting to active</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td><p>Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04032418" target="_blank">NCT04032418</a></td><td><select class="form-select" id="select_form_36" name="NCT04032418"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>Spectrum Pharmaceuticals Inc</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td>Poziotinib Once Daily Dosing; Poziotinib Twice Daily Dosing; Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04402008" target="_blank">NCT04402008</a></td><td><select class="form-select" id="select_form_37" name="NCT04402008"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 35</strong></td>
    <td>Advanced NSCLC</td>
    <td>AnHeart Therapeutics Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td>Taletrectinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04919811" target="_blank">NCT04919811</a></td><td><select class="form-select" id="select_form_38" name="NCT04919811"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting; Start Date moved earlier by 209 days</strong></td>
    <td>Stage 4 and recurrent non- small cell lung cancer</td>
    <td>University of Kansas Medical Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td><p>Atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04467723" target="_blank">NCT04467723</a></td><td><select class="form-select" id="select_form_39" name="NCT04467723"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 75</strong></td>
    <td>Advanced or Metastatic Solid Tumor</td>
    <td>Taiho Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td>AB122; AB122; AB122; TAS-116; AB122; TAS-116; AB122; TAS-116; AB122; TAS-120; AB122; TAS-115; AB122; TAS-115</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04999761" target="_blank">NCT04999761</a></td><td><select class="form-select" id="select_form_40" name="NCT04999761"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 11</strong></td>
    <td>Solid tumors</td>
    <td>Genmab</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td>GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04424641" target="_blank">NCT04424641</a></td><td><select class="form-select" id="select_form_41" name="NCT04424641"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to suspended</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations</td>
    <td>Spectrum Pharmaceuticals Inc</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td><p>Poziotinib; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05378763" target="_blank">NCT05378763</a></td><td><select class="form-select" id="select_form_42" name="NCT05378763"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Stage IA with high-risk factors and stage IB non-small cell lung cancer</td>
    <td>Peking Union Medical College Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td>Furmonertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05445310" target="_blank">NCT05445310</a></td><td><select class="form-select" id="select_form_43" name="NCT05445310"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations</td>
    <td>Allist Pharmaceuticals Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td>Furmonertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05466149" target="_blank">NCT05466149</a></td><td><select class="form-select" id="select_form_44" name="NCT05466149"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Multitude Therapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td>AMT-151</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05498597" target="_blank">NCT05498597</a></td><td><select class="form-select" id="select_form_45" name="NCT05498597"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 27</strong></td>
    <td>Advanced/recurrent solid tumors that express HER2</td>
    <td>Mersana Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td>XMT-2056</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05514717" target="_blank">NCT05514717</a></td><td><select class="form-select" id="select_form_46" name="NCT05514717"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer</td>
    <td>Chipscreen Biosciences Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td>Tucidinostat; Tislelizumab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05519865" target="_blank">NCT05519865</a></td><td><select class="form-select" id="select_form_47" name="NCT05519865"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Solid tumors that express epidermal growth factor receptor (EGFR)</td>
    <td>Dragonfly Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td><p>DF9001; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_526">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05597839" target="_blank">NCT05597839</a></td><td><select class="form-select" id="select_form_48" name="NCT05597839"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion</td>
    <td>Prelude Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td>PRT3789</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05639751" target="_blank">NCT05639751</a></td><td><select class="form-select" id="select_form_49" name="NCT05639751"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>HER2 Mutant Cancer</td>
    <td>Enliven Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td><p>ELVN-002; Fam-Trastuzumab Deruxtecan-Nxki; Trastuzumab emtansine</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05650879" target="_blank">NCT05650879</a></td><td><select class="form-select" id="select_form_50" name="NCT05650879"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>NSCLC</td>
    <td>Affiliated Hospital of Jiangnan University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td>Antitumor therapy guided by organoid drug sensitivity test</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05669586" target="_blank">NCT05669586</a></td><td><select class="form-select" id="select_form_51" name="NCT05669586"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Brain Metastases</td>
    <td>Centre hospitalier de l'Universit de Montral (CHUM)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>Nivolumab; Radiosurgery</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02978404" target="_blank">NCT02978404</a></td><td><select class="form-select" id="select_form_52" name="NCT02978404"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 762 days</strong></td>
    <td>Cancer</td>
    <td>Craig L Slingluff Jr</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td>Echopulse; Poly ICLC; Standard of Care PD-1 Therapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04116320" target="_blank">NCT04116320</a></td><td><select class="form-select" id="select_form_53" name="NCT04116320"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 567 days; Enrollment increased by: 15; Trial completed; Primary Completion Date pushed later by 504 days</strong></td>
    <td>Treatment-naive Advanced Non-small Cell Lung Cancer</td>
    <td>Shanghai Junshi Bioscience Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td>TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03856411" target="_blank">NCT03856411</a></td><td><select class="form-select" id="select_form_54" name="NCT03856411"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 91 days</strong></td>
    <td>Extensive Disease (ED)-SCLC</td>
    <td>European Organisation for Research and Treatment of Cancer - EORTC</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td><p>Pembrolizumab; cis/carboplatin and etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_530">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02580994" target="_blank">NCT02580994</a></td><td><select class="form-select" id="select_form_55" name="NCT02580994"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 288 days; Enrollment decreased by: 33; Primary Completion Date moved earlier by 487 days</strong></td>
    <td>Extensive Stage Lung Small Cell Cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td><p>Atezolizumab; Carboplatin; Entinostat; Etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_530">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04631029" target="_blank">NCT04631029</a></td><td><select class="form-select" id="select_form_56" name="NCT04631029"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 731 days</strong></td>
    <td>Nonsmall Cell Lung Cancer; Solid Tumors</td>
    <td>Second Affiliated Hospital of Guangzhou Medical University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td>TCR-T cells</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03778814" target="_blank">NCT03778814</a></td><td><select class="form-select" id="select_form_57" name="NCT03778814"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 605 days; Enrollment increased by: 80; Primary Completion Date pushed later by 513 days</strong></td>
    <td>ALK-positive non-small cell lung cancer</td>
    <td>Shouyao Holdings (Beijing) Co. LTD</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td>SY-3505</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05257512" target="_blank">NCT05257512</a></td><td><select class="form-select" id="select_form_58" name="NCT05257512"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 365 days</strong></td>
    <td>KRAS mutated unresectable locally advanced or metastatic NSCLC</td>
    <td>Biomea Fusion Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td>BMF-219</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05631574" target="_blank">NCT05631574</a></td><td><select class="form-select" id="select_form_59" name="NCT05631574"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1096 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Lung Cancer</td>
    <td>Second Affiliated Hospital of Guangzhou Medical University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td>CAR-T cells targeting GPC3 Mesothelin Claudin18.2 GUCY2C B7-H3 PSCA PSMA MUC1 TGF HER2 Lewis-Y AXL or EGFR</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03198052" target="_blank">NCT03198052</a></td><td><select class="form-select" id="select_form_60" name="NCT03198052"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 304 days; Primary Completion Date pushed later by 242 days</strong></td>
    <td>Advanced solid tumors or lymphomas</td>
    <td>Shattuck Labs Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td>SL-279252</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03894618" target="_blank">NCT03894618</a></td><td><select class="form-select" id="select_form_61" name="NCT03894618"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Resectable Stage II to IIIA non-small cell lung cancer</td>
    <td>BeiGene</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td>Tislelizumab; Ociperlimab; LBL-007</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05577702" target="_blank">NCT05577702</a></td><td><select class="form-select" id="select_form_62" name="NCT05577702"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 130 days; Enrollment decreased by: 185; Trial completed; Primary Completion Date pushed later by 113 days</strong></td>
    <td>Metastatic non-small cell lung cancer microsatellite stable colorectal cancer gastroesophageal adenocarcinoma and metastatic urothelial cancer</td>
    <td>Gritstone bio Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td><p>GRT-C901; GRT-R902; nivolumab; ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_536">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03639714" target="_blank">NCT03639714</a></td><td><select class="form-select" id="select_form_63" name="NCT03639714"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1522 days; Enrollment increased by: 26; Changed status from unknown status to active; Primary Completion Date pushed later by 700 days</strong></td>
    <td>Advanced or metastatic non-small cell lung cancer</td>
    <td>Jiangsu HengRui Medicine Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td>SHR-1210</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03085069" target="_blank">NCT03085069</a></td><td><select class="form-select" id="select_form_64" name="NCT03085069"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 35; Changed status from recruiting to active; Primary Completion Date pushed later by 365 days</strong></td>
    <td>PD-1 inhibitor resistant advanced NSCLC</td>
    <td>Chipscreen Biosciences Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td>Chidamide; Envafolimab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05068427" target="_blank">NCT05068427</a></td><td><select class="form-select" id="select_form_65" name="NCT05068427"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 366 days</strong></td>
    <td>Advanced solid tumors</td>
    <td>Second Affiliated Hospital of Guangzhou Medical University</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td><p>ipilimumab +pembrolizumab +durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_538">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05187338" target="_blank">NCT05187338</a></td><td><select class="form-select" id="select_form_66" name="NCT05187338"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 121 days</strong></td>
    <td>Mesothelioma</td>
    <td>Ain Shams University</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td>Gemcitabine; supportive care</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05660616" target="_blank">NCT05660616</a></td><td><select class="form-select" id="select_form_67" name="NCT05660616"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1326 days; Enrollment decreased by: 179; Trial terminated; Primary Completion Date moved earlier by 627 days</strong></td>
    <td>Stage IV non-small cell lung cancer</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab; BMS-986207; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05005273" target="_blank">NCT05005273</a></td><td><select class="form-select" id="select_form_68" name="NCT05005273"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 126 days; Enrollment decreased by: 106; Changed status from recruiting to active</strong></td>
    <td>Non-Small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td><p>Durvalumab; Cisplatin; Carboplatin; Etoposide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04870112" target="_blank">NCT04870112</a></td><td><select class="form-select" id="select_form_69" name="NCT04870112"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date moved earlier by 206 days</strong></td>
    <td>Pleural Mesothelioma; Non-small Cell Lung Cancer</td>
    <td>Sanofi</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td><p>THOR-707; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04914897" target="_blank">NCT04914897</a></td><td><select class="form-select" id="select_form_70" name="NCT04914897"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 186 days</strong></td>
    <td>Stage II-III NSCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td><p>Durvalumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04642469" target="_blank">NCT04642469</a></td><td><select class="form-select" id="select_form_71" name="NCT04642469"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 731 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td><p>Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_539">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04765059" target="_blank">NCT04765059</a></td><td><select class="form-select" id="select_form_72" name="NCT04765059"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from active to recruiting</strong></td>
    <td>EGFR wild-type advanced non-small cell lung cancer</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td>INC280 (capmatinib)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02414139" target="_blank">NCT02414139</a></td><td><select class="form-select" id="select_form_73" name="NCT02414139"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>EGFRm+ locally advanced or metastatic Non Small Cell Lung Cancer</td>
    <td>Janssen Research & Development LLC</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td>Lazertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04075396" target="_blank">NCT04075396</a></td><td><select class="form-select" id="select_form_74" name="NCT04075396"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 43</strong></td>
    <td>Unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td><p>Durvalumab; Placebo; Osimertinib (single-arm open-label)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_541">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03833154" target="_blank">NCT03833154</a></td><td><select class="form-select" id="select_form_75" name="NCT03833154"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial terminated</strong></td>
    <td>Locally advanced or metastatic NSCLC</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_65">Study Arms</button></td>
    <td><p>Capmatinib; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_541">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04139317" target="_blank">NCT04139317</a></td><td><select class="form-select" id="select_form_76" name="NCT04139317"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial terminated</strong></td>
    <td>Advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation T790M negative mesenchymal-to-epithelial transition factor (MET) amplified</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_66">Study Arms</button></td>
    <td><p>capmatinib; pemetrexed; cisplatin; carboplatin; osimertinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_541">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04816214" target="_blank">NCT04816214</a></td><td><select class="form-select" id="select_form_77" name="NCT04816214"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial terminated</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_67">Study Arms</button></td>
    <td>Spartalizumab; Capmatinib; spartalizumab placebo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04323436" target="_blank">NCT04323436</a></td><td><select class="form-select" id="select_form_78" name="NCT04323436"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 364 days</strong></td>
    <td>Locally Advanced or Metastatic Non-Small Cell Lung Cancer with a T790M mutation within the Epidermal Growth Factor Receptor Gene</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_68">Study Arms</button></td>
    <td>Chemotherapy; Cross-over to Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02151981" target="_blank">NCT02151981</a></td><td><select class="form-select" id="select_form_79" name="NCT02151981"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 91 days</strong></td>
    <td>Squamous-Cell Non-Small-Cell Lung Cancer</td>
    <td>Amgen</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_69">Study Arms</button></td>
    <td><p>Bemarituzumab; Docetaxel; Pembrolizumab; Carboplatin; Paclitaxel; Nab-paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_543">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05267470" target="_blank">NCT05267470</a></td><td><select class="form-select" id="select_form_80" name="NCT05267470"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>DAC-THU + pembrolizumab at escalating doses|DAC-THU + pembrolizumab at the dose established in Arm 1</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Decitabine (DAC); Drug: Pembrolizumab; Drug: Tetrahydrouridine (THU)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate|Maximum tolerated dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>safety; determine if this combination is associated with a response rate which exceeds that of Pembrolizumab alone in patients who have PD-L1 expression of at least 50% and those who do not</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After 3 weeks at cycle 1 at each dose level dose level; Every 9 weeks until at disease progression</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1 etoposide IV over 60 minutes on days 1-3 atezolizumab IV over 30-60 minutes on day 1 and entinostat PO on days 1 8 and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.||MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1 8 and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Biological: Atezolizumab; Drug: Entinostat; Drug: Etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD)|Grade 3/4 adverse event rate|Number of cycles received of the combination of entinostat atezolizumab carboplatin and etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of participants who receive 3 or more cycles of the combination will be calculated with a 90% confidence interval.; Defined by Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by frequency and magnitude.; The Bayesian optimal interval (BOIN) design will be used to find the MTD based on safety.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to cycle 4 (1 cycle = 21 days); Up to 21 days; Up to 30 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>For dose escalation phase subjects are enrolled for different doses of the experimental drug.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: XZP-5809-TT1 Tablet</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>adverse event|Objective response rate (ORR)|Progression-free survival (PFS)|blood routine|blood routine|blood routine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>the amount of red blood cell.; Refers to adverse clinical events that occur during drug treatment which may not have a causal relationship with the drug; The time from the time a subject receives the first study treatment to the appearance of disease progression or death from any cause (whichever occurs first).; the amount of platelet.; the amount of white cell.; According to the RECIST 1.1 standard the best overall response (BOR) observed after enrollment of subjects is the proportion of subjects with complete remission (CR) or partial remission (PR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>through study completion an average of 1.5 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive 80mg osimertinib orally once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Therapeutic Conventional Surgery; Drug: Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Major pathological response rate (MPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Tumors that exhibit = 10% viable tumor will meet the criteria for a major pathological response. MPR rate will be determined in patients who receive at least one dose of study drug and become ineligible for surgery either because of disease progression or adverse event will be deemed not to have achieved MPR. The major pathological response rate will be reported with 95% confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>GRT-C901|GRT-R902|nivolumab|ipilimumab|GRT-C901|GRT-R902|nivolumab|ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ipilimumab; Biological: nivolumab; Biological: GRT-C901; Biological: GRT-R902</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) serious adverse events (SAEs) and dose-limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Initiation of study treatment through 100 days post-last dose (up to approximately 27 months); Initiation of study treatment until disease progression (up to approximately 27 months); Up to approximately 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>"This arm will involve all participants in the study who have extensive small cell lung cancer that has not responded to previous treatments. All participants will receive the same treatment of study drugs and radiation treatment in ""cycles"" (a specific window of time).||You will receive up to four 21-day cycles of chemotherapy using carboplatin etoposide and durvalumab (immunotherapy) as part of a standard care treatment plan recommended by your doctor. These drugs will be combined with ablative radiation treatment during the second cycle of chemotherapy.||After completing these four cycles of chemotherapy (with radiation treatment added in cycle 2) you will continue to receive a fixed dose of durvalumab until your cancer progresses you experience serious side effects you decide to no longer be part of the study or the study doctor request to take you off the study for medical reasons."</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Ablative Radiation; Drug: Etoposide; Drug: Carboplatin; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival of Participant Until Disease Progression or Death</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The progression-free survival (PFS) of subjects with extensive-stage small cell lung cancer treated with durvalumab carboplatin and etoposide with hypofractionated ablative radiation therapy. Progression-free survival will be defined as the time from start of treatment until disease progression per Response Evaluation Criteria in Solid Tumors (RECISTv1.1) or death from any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>48 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Arms determined by autoimmune type. First cohort consists of patients with:||Rheumatoid arthritis psoriasis giant cell arteritis/polymyalgia rheumatica systemic lupus erythematosis||If a patient has more than one autoimmune condition if all the conditions are within either cohort 1 or 2 above the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2 the patient will be grouped in cohort 2.|Arms determined by autoimmune type. Second cohort consists of patients with:||Other autoimmune diseases (ulcerative colitis Crohn's disease multiple sclerosis). Patients must be discussed with PI prior to enrollment.||If a patient has more than one autoimmune condition if all the conditions are within either cohort 1 or 2 above the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2 the patient will be grouped in cohort 2.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-Limiting Toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The DLT determination period is the first six weeks after cycle 1 day 1. Dose limiting toxicities are further defined in the trial protocol.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>48 Months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) Pemetrexed (500mg/m^2 IV on day 1 of every 21 days) and Carboplatin (AUC5 IV on day 1 of every 21 days).||This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pemetrexed; Drug: Rucaparib; Drug: Carboplatin; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Median duration of time from start of treatment to time of progression</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint is median progression free survival (PFS) which is defined as the median duration of time from the start of treatment to progression. Progression is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SI-B001</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase Ia: Dose limiting toxicity (DLT)|Phase Ia: Maximum tolerated dose (MTD)|Phase Ib: Recommended Phase II Dose (RP2D)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle (28 days) and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly probably or definitely related to study drug administration.; The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study based on safety tolerability efficacy PK and PD data collected during the dose escalation study of SI-B001.; MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle (within 28 days of the first administration).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 28 days after the first dose of SI-B001</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive poziotinib hydrochloride PO BID on day 1 and ramucirumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: 1429757-68-5 HM781-36B NOV-1201 Hydrochloride NOV120101 Hydrochloride Poziotinib HCl POZIOTINIB HYDROCHLORIDE; Drug: Poziotinib Hydrochloride</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Estimated using the Kaplan and Meier method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From start of treatment to time of progression or death whichever occurs first assessed up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants in the Dose Escalation Cohort 1 will receive U3-1402 intravenously (IV) once every three weeks at 3.2 mg/kg.|Participants in Dose Escalation Cohort 2 will receive U3-1402 intravenously (IV) once every three weeks at 4.8 mg/kg.|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 5.6 mg/kg.|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 6.4 mg/kg.|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE) or if applicable adjusted RDE (aRDE).|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive U3-1402 IV once every three weeks following an up-titration regimen (Cycle 1 Day 1: 57% of RDE or aRDE; Cycle 2 Day 1: 86% of RDE or if applicable aRDE; Cycle 3 and subsequent cycles Day 1: 114% of RDE or aRDE).|Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive U3-1402 IV at 5.6 mg/kg every 3 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: U3-1402 (CTM-1 Lyo-DP); Drug: U3-1402 (FL-DP); Drug: U3-1402 (CTM-3 Lyo-DP)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting toxicities (DLTs) during dose escalation|Summary of adverse events during dose escalation|Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion|Maximum serum concentration (Cmax) of U3-1402 total anti-HER3 antibody and MAAA 1181a during dose expansion (Cohort 4)|Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of U3-1402 total anti-HER3 antibody and MAAA 1181a during dose expansion (Cohort 4)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR will be evaluated using RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>By the global end of trial date approximately within 36 months; 21 days of Cycle 1; Approximately within 36 months; Cycle 1: Day 1 pre-dose and end of infusion (EOI) 2 hours 4 hours 8 hours; Day 8 Day 15; Cycle 2: Day 1 pre-dose (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Survey Administration; Biological: Atezolizumab and Recombinant Human Hyaluronidase</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) of home administration by a healthcare provider (HCP) of subcutaneous atezolizumab|Successful completion of home drug administration visits within the specified window</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determined by rates of grade 3 or greater non-hematologic AE assessment by clinical assessment. Grading will be based on the NCI CTCAE v5.0 .; The number of successfully completed home visits per patient and the number of patients who successfully completed all home administrations will be calculated and reported.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days after last dose; Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Therapeutic Conventional Surgery; Radiation: Radiation Therapy; Drug: Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be estimated using Kaplan-Meier method. The stratified log-rank test will be performed to test the difference in time-to-event distributions between treatment groups. Stratified Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis and to estimate hazard ratios.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From the start date of osimertinib assessed up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Poziotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate a in patients with estimated glomerular filtration rate (EGFR) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 1)|Objective response rate a in patients with human epidermal growth factor receptor 2 (HER2) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>According to Response Evaluation Criteria in Solid Tumors 1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>1-year progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measured using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose finding at 8 mg 12 mg or 16 mg of poziotinib once daily in 28-day treatment cycles.|Dose finding at 4 mg 6 mg or 8 mg of poziotinib twice daily in 28-day treatment cycles.|Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.||Cohort 1: EGFR exon 20 insertion mutations||Cohort 2: HER2 exon 20 insertion mutations</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Poziotinib Once Daily Dosing; Drug: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1; Drug: Poziotinib Twice Daily Dosing</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)|Phase 2: Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of patients who achieve Complete Response (CR) or Partial response (PR) by the best response from the first dose of poziotinib to the end of the study.; MTD/MAD will be assessed based on the occurrence of defined dose-limiting toxicities (DLT) and all available safety information during first cycle of treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 Days; 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Single-arm trial whereby all consented enrolled eligible patients receive taletrectinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Taletrectinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR) by independent radiology review committee (IRC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Confirmed ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by an independent radiology review committee (IRC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.||Pirfenidone (Esbriet) orally (PO) with food according to this schedule:||Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurrence of Grade 3 toxicity|Occurrence of Grade 4 toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 day 1 to Cycle 3 day 1 (Each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AB122 will be given in participants with advanced or metastatic solid tumor.|AB122 will be given in participants with advanced or metastatic solid tumor.|AB122 will be given in combination with TAS-116 in participants with pancreatic ductal adenocarcinoma.|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic MSS/pMMR CRC without liver metastases.|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic non-squamous NSCLC without actionable gene alterations.|AB122 will be given in combination with TAS-120 in participants with unresectable metastatic NSCLC with PD-L1 high expression and without actionable gene alterations.|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic NSCLC without actionable gene alterations.|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic ASPS in those who received or no prior regimen for advanced disease.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TAS-120; Drug: AB122; Drug: TAS-116; Drug: TAS-115</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1a (general) : Percentage of participants who experience a Dose Limiting Toxicity (DLT)|Phase 1b (Cohort B-n D-1 and E-n ) : Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through completion of treatment (estimated to be 4 months); From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants With Abnormal Laboratory Values</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above [medical and scientific judgment must be exercised in deciding whether an AE is 'medically significant']); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of GEN1044 and 30 days after the last dose received.; The DLT was defined as Grade (G) = 3 cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome; any G3 or 4 hematologic and non-hematologic toxicity (with exceptions defined by the protocol); laboratory abnormality that required clinically significant medical intervention led to hospitalization persisted for 1 week or resulted in a drug-induced liver injury; G3 or 4 febrile neutropenia; liver toxicity defined by Hy's law; any treatment-related toxicity that caused treatment discontinuation during Cycle 1; or any G5 toxicity.; In case a participant reported multiple severity grades for a laboratory value only the maximum grade was used.; Number of participants with laboratory values of Grade = 3 by NCI-CTCAE v5.0 are reported. The NCI-CTCAE is a descriptive terminology that is used for gradings (Grade 1-5) of Adverse Events (AEs) and of laboratory values; the latter being summarized here.; This table reports laboratory values graded only on the numerical value of the reported parameter and is therefore not graded by symptoms or signs. The abnormal laboratory values assessed by the investigator as being AEs are reported also in the AE table.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 1 through Day 263 (corresponding to maximum observed duration); From Day 1 to Day 21 of first cycle</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive poziotinib 8 mg orally BID in 21 day cycles or until disease progression death intolerable adverse events (AEs) initiation of non-protocol anti-cancer treatment or other protocol-specified reasons for participant withdrawal from the study.|Participants will receive docetaxel 75 mg/m^2 intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression death intolerable AEs initiation of non-protocol anti-cancer treatment or other protocol-specified reasons for participant withdrawal from the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Docetaxel; Drug: Poziotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time (in months) from the start of the study treatment to the date of first documented disease progression by central radiographic evaluation per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) or death due to any cause whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive furmonertinib 80mg/d for 3 years or until disease recurrence or treatment cessation for other reasons.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Furmonertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease-free survival rate at 3 years</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The rate of survival patients without disease recurrence at 3 years</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years following the first dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Treating patients of locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Furmonertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>ORR Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with a confirmed CR or PR relative to the total number of patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 7.5 months following the last patient enrolled</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AMT-151</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Recommended Phase 2 Dose (RP2D)|Maximum Tolerated Dose (MTD)|Incidence of Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD will be determined using DLTs; Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0; The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>XMT-2056 alone (monotherapy)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: XMT-2056</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)|Incidence of adverse events (Dose Escalation and Dose Expansion)|Objective Response Rate (ORR) (Dose Expansion)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determine the maximum tolerated dose (MTD) of XMT-2056; The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Assess the safety and tolerability of XMT-2056 by determining the number of patients with adverse events from date of first dose to 30 days post last dose.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years; 15 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects receive Tucidinostat 30mg orally biw and Tislelizumab 200 mg intravenously (IV) Q3W.|Subjects receive Tislelizumab 200 mg intravenously (IV) Q3W.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tucidinostat; Drug: Tislelizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS) per RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS assessed by investigator per RECIST v1.1 measured from the date of randomization until progression or death whichever is first met.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose escalation cohorts of DF1001 in sequential ascending order.|Expansion cohorts of monotherapy DF9001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.|Monotherapy expansion cohort enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.|Monotherapy expansion cohort enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.|Monotherapy expansion cohort enrolling up to 40 patients with Non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.|Combination dose escalation of DF9001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.|Expansion cohorts of DF9001 in combination with a PD-1 checkpoint inhibitor in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: DF9001</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocol|Assess Overall Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the number of adverse events experienced during the study that meet dose limiting toxicity criteria per the study protocol.; To assess the Overall Response Rate (ORR) per RECIST 1.1 criteria.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through 90 days after completion of the study an average of 1 year.; First 4 weeks of treatment for each subject.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PRT3789 will be administered by intravenous infusion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PRT3789</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicity (DLT) of PRT3789|Safety and tolerability of PRT3789: AEs CTCAE Assessments|Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety and tolerability will be evaluated by incidence of DLTs laboratory measurements dose interruption modification and discontinuation due to adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE); The MTD/RP2D will be established for further investigation in participants with advanced solid tumors; Dose limiting toxicities will be evaluated over the 21-day observation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline through Day 21; Baseline through approximately 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.|ELVN-002 will be administered either once or twice daily. A maximum of 30 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.|ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels.||ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Trastuzumab emtansine; Drug: ELVN-002; Drug: Fam-Trastuzumab Deruxtecan-Nxki</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose limiting toxicities in Phase 1a monotherapy|Incidence of adverse events in Phase 1a monotherapy|incidence of laboratory abnormalities in Phase 1a monotherapy|incidence of ECG abnormalities in Phase 1a monotherapy|incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd)|Incidence of adverse events in Phase 1a combination with T-DXd|incidence of laboratory abnormalities in Phase 1a combination with T-DXd|incidence of ECG abnormalities in Phase 1a combination with T-DXd|incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1)|Incidence of adverse events in Phase 1a combination with T-DM1|incidence of laboratory abnormalities in Phase 1a combination with T-DM1|incidence of ECG abnormalities in Phase 1a combination with T-DM1|Incidence of adverse events in Phase 1b monotherapy|incidence of laboratory abnormalities in Phase 1b monotherapy|incidence of ECG abnormalities in Phase 1b monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>42 days; 21 days; 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; No Intervention</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Non-small cell lung cancer specimens are obtained from lung tumor surgery or biopsy and are used to grow organoids. Then organoids are used for drug sensitivity tests to obtain the sensitivity to drugs. Patients will receive a relatively sensitive antitumor regimen based on the test results.|According to the National Comprehensive Cancer Network's (NCCN) Guidelines for non-small cell lung Cancer physicians will determine antitumor protocols. They're also not sure what the drug susceptibility test says.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Antitumor therapy guided by organoid drug sensitivity test</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time from randomization to any disease progression and/or death defined according to strict RECIST (Response Evaluation Criteria in Solid Tumors) v1.1. Lesion will be assessed in comparison to baseline measurements.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)||Upon entering this trial patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Radiation: Radiosurgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Intracranial progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate whether the combination SRS with Nivolumab will improve the intracranial progression-free survival of patients.; Response will be assessed as per RECIST version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.|FUSA therapy standard of care PD-1 blockade and intratumoral poly-ICLC will be administered on day 8.|FUSA therapy will be administered on day 1.|FUSA therapy and intratumoral poly-ICLC will be administered on day 1.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Echopulse; Drug: Poly ICLC; Drug: Standard of Care PD-1 Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To assess the safety and toxicity of FUSA administered alone or in combination with PD-1 antibody blockade.|To estimate the proportion of patients with increased CD8+ T cell infiltration of spot FUSA-treated metastasis.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence and severity of adverse events and incidence of dose-limiting toxicities (DLTs).; Proportion of participants achieving at least a 2-fold increase in CD8+ T cell infiltration per mm2.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 days after the last study intervention; Day 43 (cohort 1) or Day 36 (cohort 2)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PFS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 approximately years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pembrolizumab in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks) pembrolizumab continued alone as continuation maintenance until progressive disease|4 cycles of cis/carboplatin and etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: cis/carboplatin and etoposide; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Increase in Progression Free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1 etoposide IV over 60 minutes on days 1-3 atezolizumab IV over 30-60 minutes on day 1 and entinostat PO on days 1 8 and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.||MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1 8 and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Biological: Atezolizumab; Drug: Entinostat; Drug: Etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD)|Grade 3/4 adverse event rate|Number of cycles received of the combination of entinostat atezolizumab carboplatin and etoposide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of participants who receive 3 or more cycles of the combination will be calculated with a 90% confidence interval.; Defined by Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by frequency and magnitude.; The Bayesian optimal interval (BOIN) design will be used to find the MTD based on safety.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to cycle 4 (1 cycle = 21 days); Up to 21 days; Up to 30 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: TCR-T cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients with Dose Limiting Toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the TCR-T cells which is irreversible or life threatening or hematologic or non-hematologic Grade 3-5.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>three months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SY-3505 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose. In phase II SY-3505 will be given at RP2D in advanced ALK-positive NSCLC patients.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SY-3505</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I: Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment|Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)|Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Characterization of the safety and tolerability; Anti-tumor activity of SY-3505; Maximum Tolerated Dose(s) (MTD(s)) and/or recommended phase 2 dose (RP2D(s)) in Cycle 1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months; Dose-escalation Cycle 1 (each cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation Phase will group all disease indications (NSCLC PDAC and CRC) together to assess the safety of each dose level.||Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).|Dose Expansion Phase will enroll additional subjects independently in each disease indication:||Cohort 1: Participants with NSCLC||Cohort 2: Participants with PDAC||Cohort 3: Patients with CRC||Cohorts 1 2 and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BMF-219</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.|To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.; OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection from 1x10e6/kg-10x10e6/kg weight.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: CAR-T cells targeting GPC3 Mesothelin Claudin18.2 GUCY2C B7-H3 PSCA PSMA MUC1 TGFβ HER2 Lewis-Y AXL or EGFR</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients with Dose Limiting Toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR T cellswhich is irreversible or life threatening or hematologic or non-hematologic Grade 3-5.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>three months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SL-279252</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety profile of SL-279252 - Incidence of all treatment emergent adverse events|Maximum Tolerated Dose (MTD) of SL-279252</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined based on the rate of dose limiting toxicities (DLTs); Incidence of all treatment emergent adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From Day 1 to 90 days after Last Dose of SL-279252 (approximately 1 year)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Tislelizumab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + ociperlimab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + LBL-007 on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Ociperlimab; Drug: Tislelizumab; Drug: LBL-007</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Major Pathological Response (MPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MPR is defined as the proportion of participants with ≤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 12 weeks after first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>GRT-C901|GRT-R902|nivolumab|ipilimumab|GRT-C901|GRT-R902|nivolumab|ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ipilimumab; Biological: nivolumab; Biological: GRT-C901; Biological: GRT-R902</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) serious adverse events (SAEs) and dose-limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Initiation of study treatment through 100 days post-last dose (up to approximately 27 months); Initiation of study treatment until disease progression (up to approximately 27 months); Up to approximately 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: SHR-1210</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Determined using RECIST v1.1 criteria up to approximately 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive Chidamide 20mg or 30mg orally twice per week and Envafolimab 400mg subcutaneous infusions every 4 weeks untile disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Envafolimab; Drug: Chidamide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Response is assessed once every 8 weeks assessed up to 24 weeks.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Three antibodies combination against PD1 PDL1 and CTLA4.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ipilimumab +pembrolizumab +durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of 3 drugs combination treatment|Progression-free survival|Disease control rate|Duration of remission (DOR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be assessed by recording all types of advise effects upon and after the treatment.; Disease control rate will be defined as objective response rate + steady disease rate.; DOR will be defined as the duration of the cancer remission; Progression-free survival (PFS) will be defined as the elapsed time from the first date of study treatment until documented disease progression (as per RECIST 1.1) or death from any cause whichever is earlier. For patients who remain alive without progression follow-up time will be censored at the date of last disease assessment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8 in cycles of 21 days plus supportive care.|best supportive care alone.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: supportive care; Drug: Gemcitabine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>progression free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>It is the time from randomization to disease progression or death from any cause</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Placebo; Drug: Nivolumab; Drug: BMS-986207; Drug: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 25 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with Non-Small Cell Lung Cancer|Patients with Small Cell Lung Cancer</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Observed serum concentration (Ctrough)|Number of patients with injection site reactions and immune-mediated reactions|Maximum observed serum concentration (Cmax)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 16 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: THOR-707; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Objective response rate (ORR) defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR) derived based on Investigator's assessment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for Cohort A1 Cohort A2 and Cohort B1; per modified RECIST (mRECIST) for Cohort C1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Intravenous administration of Durvalumab|Intravenous administration of placebo</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Other: Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>DFS in PD-L1 TC≥1% (using Investigator assessments according to RECIST 1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the efficacy of durvalumab compared to placebo as measured by DFS in the PD-L1 TC≥1% analysis set</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5) both administered on Day 1 of 21-day cycles for 4 cycles followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles|All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5) both administered on Day 1 of 21-day cycles for 4 cycles followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS): time from randomization until progression (intracranial or extracranial whichever occurs first) per RECIST 1.1 (for extracranial progression) and CNS RECIST 1.1 (for intracranial progression)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on PFS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At Screeningevery 6 weeks for the first 13 cycles (each cycle is 21 days)then every 12 weeks relative to randomizationand upto intracranial or extracranial disease progression or end of survival follow-upwhichever comes first (approximately 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line|Pre-treated patients with cMET GCN ≥ 4 and  6 treated with INC280 at 400 mg BID as second or third line|Pre-treated patients with cMET GCN  4 treated with INC280 at 400mg BID as second or third line|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line|Treatment-naïve patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: INC280 (capmatinib)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Proportion of patients with a best overall response defined as complete response (CR) or partial response (PR) by Blinded Independent Review Committee (BIRC) assessment per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>at least 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety tolerability efficacy and pharmacokinetics (PK) of Lazertinib.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lazertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part D: Number of Participants with Adverse Event as a Measure of Safety and Tolerability|Part D: Plasma Concentration of Lazertinib After Administration of Single Dose (SD)|Part D: Plasma Concentration of Lazertinib After Administration of Multiple Dose (MD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Plasma Concentration of Lazertinib after administration of single dose will be evaluated.; Plasma Concentration of Lazertinib after administration of multiple dose will be evaluated.; An adverse event is any untoward medical event that occurs in a participants administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SBRT - delivered in 3 4 5 or 8 fractions.||Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met.|SBRT - delivered in 3 4 5 or 8 fractions.||Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met.|SBRT delivered in 3 4 5 or 8 fractions||Osimertinib 80mg every day [qd] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Other: Placebo; Drug: Osimertinib (single-arm open-label)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC|4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Main Cohort; Osimertinib Cohort</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from randomization up to 5 years; from randomization up to 6 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_65" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Capmatinib 400 mg twice a day Pembrolizumab 200mg every 3 weeks|Pembrolizumab 200mg every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab; Drug: Capmatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS) based on local investigator assessment as per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival is defined as the time from randomization to the date of the first documented radiological progression using RECIST 1.1(Response evaluation criteria in solid tumor) or death due to any cause</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>18 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_66" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).|For randomized part: following local guidelines as per standard of care and products labels Participants randomized to platinum-pemetrexed based doublet chemotherapy arm will be allowed to crossover to receive capmatinib in combination with osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: osimertinib; Drug: pemetrexed; Drug: carboplatin; Drug: capmatinib; Drug: cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Run-in part: Incidence of dose limiting toxicities (DLTs)|Randomized part: Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence of Dose Limiting Toxicities (DLT) during the first 21 days (3 weeks) of treatment for each dose level associated with administration of capmatinib in combination with osimertinib; Progression free survival (PFS) per Blinded Independent Review Committee (BIRC) according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>37 months; 3 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_67" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>capmatinib in combination with spartalizumab|capmatinib in combination with spartalizumab|capmatinib in combination with placebo</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Spartalizumab; Drug: spartalizumab placebo; Drug: Capmatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate by Investigator assessment as per RECIST 1.1|Progression Free survival (PFS) by BIRC as per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Run-in part To evaluate the anti-tumor activity of capmatinib in combination with spartalizumab; Randomized part To compare the efficacy of capmatinib in combination with spartalizumab versus capmatinib plus placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2.5 years; 6 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_68" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Osimertinib 80 mg orally once daily|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cross-over to Osimertinib; Drug: Chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS) by Investigator Assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): = 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of =5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of randomisation until the date of PD (by investigator assessment) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_69" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with SqNSCLC will receive escalating doses of bemarituzumab in combination with docetaxel.|Participants with SqNSCLC and FGFR2b overexpression will receive the dose of bemarituzumab in combination with docetaxel identified as safe during Part 1.|Participants with SqNSCLC and FGFR2b overexpression will receive bemarituzumab monotherapy.|Participants with FGFR2b overexpression will receive the dose of bemarituzumab identified as safe during Part 1 in combination with pembrolizumab carboplatin and either paclitaxel or nab-paclitaxel.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nab-paclitaxel; Drug: Pembrolizumab; Drug: Paclitaxel; Drug: Bemarituzumab; Drug: Carboplatin; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 and 4: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)|Parts 1 2 3 and 4: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Adverse events (AEs) are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs physical examinations clinical laboratory tests and visual acuity that occur after study treatment administration will be recorded as TEAEs.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 Day 1 to Cycle 1 Day 21 (cycle is 21 days); Cycle 1 Day 1 to 28 days after last dose (approximately 5 months; cycle is 21 days in Parts 1 and 2 cycle is 14 days in Part 3)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_it">New Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced Liver Cancer</td>
    <td>Binhui Biopharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_70">Study Arms</button></td>
    <td>OH2 injection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05698459" target="_blank">NCT05698459</a></td><td><select class="form-select" id="select_form_81" name="NCT05698459"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Malignant Solid Tumors</td>
    <td>Immorna Biotherapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_71">Study Arms</button></td>
    <td>JCXH-211 Injection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05727839" target="_blank">NCT05727839</a></td><td><select class="form-select" id="select_form_82" name="NCT05727839"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_70" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Administration：intratumoral injection Frequency：once every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: OH2 injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>DLTs (Dose Limiting Toxicity)|MTD (Maximum Tolerance dose)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxic reactions according to the NCI-CTCAE 5.0 grading standard that occur within 3 weeks from the first administration are judged to be drug-related by the investigator and meet the non-hematological toxicity and hematological toxicity conditions specified in the clinical protocol; If ≥2/6 subjects developed DLT the previous dose group was MTD</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years; 3 weeks from the first administration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_71" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>"JCXH-211 will be delivered by intratumoral injection in 2 stages:||（Part1）Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results1-2 dose groups were selected for deep lesion injection study dose escalation will follow the ""3 + 3"" principle.|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase Ia."</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: JCXH-211 Injection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicity|Incidence of adverse events （Safety and Tolerability）</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose limiting toxicity evaluated in the Phase Ia which will be used to determine the MTD and to determine dose escalation.; Safety and tolerability as determined by the incidence of adverse events （AEs） including severe AEs and serious AEs （SAEs）.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 28 days after the first dose; From consent to 28 days after the last dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1131 days; Trial completed</strong></td>
    <td>Squamous cell carcinoma of the head and neck that has returned (come back) after a period of improvement or has spread to other parts of the body or breast cancer that has spread to other parts of the body</td>
    <td>Mayo Clinic</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_72">Study Arms</button></td>
    <td>Laboratory Biomarker Analysis; Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01846091" target="_blank">NCT01846091</a></td><td><select class="form-select" id="select_form_83" name="NCT01846091"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Stage III/IV Melanoma</td>
    <td>Gustave Roussy Cancer Campus Grand Paris</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_73">Study Arms</button></td>
    <td><p>Ipilimumab IT; Ipilimumab IV; Nivolumab IV</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_546">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02857569" target="_blank">NCT02857569</a></td><td><select class="form-select" id="select_form_84" name="NCT02857569"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Hepatocellular Carcinoma</td>
    <td>Mayo Clinic</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_74">Study Arms</button></td>
    <td>External Beam Radiation Therapy; Pneumococcal 13-valent Conjugate Vaccine; Therapeutic Autologous Dendritic Cells</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03942328" target="_blank">NCT03942328</a></td><td><select class="form-select" id="select_form_85" name="NCT03942328"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days</strong></td>
    <td>Diffuse Intrinsic Pontine Glioma</td>
    <td>University of Colorado Denver</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_75">Study Arms</button></td>
    <td>Gemcitabine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02992015" target="_blank">NCT02992015</a></td><td><select class="form-select" id="select_form_86" name="NCT02992015"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 487 days; Primary Completion Date pushed later by 427 days</strong></td>
    <td>Locally advanced or metastatic cutaneous malignancies</td>
    <td>Replimune Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_76">Study Arms</button></td>
    <td>RP1 intra-tumoral injection oncolytic virus</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04349436" target="_blank">NCT04349436</a></td><td><select class="form-select" id="select_form_87" name="NCT04349436"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 184 days; Enrollment increased by: 51; Changed status from recruiting to active; Primary Completion Date pushed later by 1005 days</strong></td>
    <td>Locally advanced or metastatic CSCC</td>
    <td>Replimune Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_77">Study Arms</button></td>
    <td>Cemiplimab; RP1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04050436" target="_blank">NCT04050436</a></td><td><select class="form-select" id="select_form_88" name="NCT04050436"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 200 days; Enrollment decreased by: 30; Now recruiting; Primary Completion Date pushed later by 139 days; Start Date pushed later by 495 days</strong></td>
    <td>AFP positive solid tumors</td>
    <td>Beijing Syngentech Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_78">Study Arms</button></td>
    <td>SynOV1.1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04612504" target="_blank">NCT04612504</a></td><td><select class="form-select" id="select_form_89" name="NCT04612504"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 92 days</strong></td>
    <td>Non-muscle-invasive Bladder Cancer</td>
    <td>Aura Biosciences</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_79">Study Arms</button></td>
    <td>AU-011; AU-011 in Combination with Medical Laser</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05483868" target="_blank">NCT05483868</a></td><td><select class="form-select" id="select_form_90" name="NCT05483868"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Advanced Colorectal Carcinoma</td>
    <td>Binhui Biopharmaceutical Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_80">Study Arms</button></td>
    <td><p>OH2; Capecitabine; Bevacizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_552">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05648006" target="_blank">NCT05648006</a></td><td><select class="form-select" id="select_form_91" name="NCT05648006"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo5"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 333 days</strong></td>
    <td>Advanced/metastatic or recurrent malignancies</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_81">Study Arms</button></td>
    <td><p>Gebasaxturev; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_552">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04521621" target="_blank">NCT04521621</a></td><td><select class="form-select" id="select_form_92" name="NCT04521621"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Incurable non-metastatic hepatocellular carcinoma</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_82">Study Arms</button></td>
    <td><p>Lenvatinib; Pembrolizumab; Oral Placebo; IV Placebo; TACE</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_552">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04246177" target="_blank">NCT04246177</a></td><td><select class="form-select" id="select_form_93" name="NCT04246177"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_72" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter; Other: Laboratory Biomarker Analysis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0|Number of toxicity incidents defined as adverse events that are classified as either possibly probably or definitely related to study treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessed by the NCI CTCAE v. 4.0. Toxicity data will be summarized for MV-NIS virus cohorts.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 months; 4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_73" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response eradication of all injectable sites disease progression or toxicity for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).|nivolumab: 1mg/kg IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months.|ipilimumab: 3mg/kg IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.|nivolumab: 1mg/kg IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab IV; Drug: Ipilimumab IV; Drug: Ipilimumab IT</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>6-months treatment-related grade 3-4 toxicity event-free survival (EFS).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Assessed every 28 days after randomization up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_74" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients undergo standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of significant toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A significant toxicity is defined as a dose limiting toxicity that is possibly probably or definitely related to dendritic cell (DC) treatment. Toxicities will be assessed using the Cancer Therapy Evaluation Program active version of the Common Terminology Criteria for Adverse Events.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to completion of cycle 2 (each cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_75" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Gemcitabine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PK testing levels of gemcitabine its metabolite difluorodeoxyuridine (dFdU) and gemcitabine necleotides in peripheral blood and DIPG tissue</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The investigators will use liquid chromatography/tandem mass spectrometry (LC-MS/MS). An API 4000 instrument will be used which has an approximate sensitivity of 0.1 ng/mg. Given the dimensions of the biopsy needle used 10 mm length and 0.75 mm diameter the investigators expect that each core will have an approximate volume of 4.5 mm2 which translates to a likely mass of 4.5 mg. Given that approximately 10 mg of tumor tissue has been necessary for quantification of gemcitabine and its matabolites in past studies multiple cores of the six available for quantification from neighboring regions of the tumor may be combined; whenever possible. However more than one separate measurement of concentrations will be done for each patient to determine any variation in concentrations across the tumor. An internal control measurement for gemcitabine will be determined using a variant gemcitabine compound enriched with 13C (Carbon 13).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2-12 hours post systemic admininstration of gemcitabine.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_76" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RP1 administered as an intra-tumoral injection every 2 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: RP1 intra-tumoral injection oncolytic virus</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Primary Safety Outcome Measure|Primary Efficacy Outcome Measure|Incidence of subjects with treatment-emergent adverse events greater than or equal to Grade 3|Incidence of subjects with Serious adverse events (SAEs)|Incidence of subjects with fatal adverse events|Treatment-emergent adverse events requiring withdrawal from IP and incidence of organ allograft rejection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assess the safety and tolerability of single-agent RP1 in solid organ transplant patients with cutaneous malignancies by incidence of subjects with treatment-emergent adverse events; The objective response rate (ORR) according to investigator assessment using modified RECIST version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_77" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks|Cemiplimab administered intravenously as a single therapy every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cemiplimab; Biological: RP1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) according to blinded independent review|Complete Response Rate (CRR) according to blinded independent review</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_78" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: SynOV1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The dose-limiting toxicities (DLTs) of SynOV1.1 in patients with HCC|The maximum-tolerated dose (MTD) of SynOV1.1 in patients with HCC|The response rate of patients with HCC receiving SynOV1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD for patients with HCC received SynOV1.1 treatment.; Incidence and nature of DLT of SynOV1.1 in in patients with HCC graded according to NCI CTCAE v5; response rate based on RECIST ver. 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_79" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Administration of AU-011 alone intramurally with or without intratumoral administration prior to the standard of care procedure (cystectomy or TURBT)|AU-011 intramural administration with laser application prior to the standard of care TURBT|AU-011 intramural administration with laser application prior to standard of care Cystectomy|AU-011 intramural and intratumoral administration with laser application prior to standard of care TURBT</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AU-011; Combination Product: AU-011 in Combination with Medical Laser</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of AU-011: Incidences of SAEs and DLTs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence and severity of treatment-related adverse events and serious adverse events (SAEs) and incidence of dose-limiting toxicities (DLTs).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>56 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_80" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>OH2: 10^7 CCID50/mL intratumoral injection once every 2 weeks; Capecitabine: 1000 mg/m2 orally administered twice a day D1 to D14 repeated every 3 weeks|Capecitabine: 1000 mg/m2 orally administered twice a day D1 to D14 repeated every 3 weeks Bevacizumab: 7.5 mg/kg intravenously once every 3 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Bevacizumab; Drug: Capecitabine; Biological: OH2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time after treatment to clinical and radiographic disease progression will be evaluated.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_81" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of gebasaxturev intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days and cycles 2-35 are 21 days.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Biological: Gebasaxturev</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator|Number of Participants who Experience a Dose-Limiting Toxicity (DLT)|Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs)|Part 2: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLTs are defined as toxicities that: are possibly probably or definitely related to study intervention administration; and meet pre-defined study criteria.; ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.; An AE is defined as any unfavorable and unintended sign symptom disease or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 2 arms will be analyzed in this outcome measure.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 44 months; Up to approximately 103 weeks; Up to approximately 107 weeks; Up to approximately 4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_82" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive a combination of lenvatinib pembrolizumab and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight 60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).|Participants will receive a combination of lenvatinib-matching oral placebo pembrolizumab-matching IV placebo and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Oral Placebo; Drug: Lenvatinib; Drug: IV Placebo; Procedure: TACE; Biological: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OS is defined as the time from randomization to death due to any cause.; PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to ~43 months; Up to ~95 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Unresectable or metastatic melanoma</td>
    <td>Biocad</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_83">Study Arms</button></td>
    <td>BCD-217; BCD-100; Placebo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05732805" target="_blank">NCT05732805</a></td><td><select class="form-select" id="select_form_94" name="NCT05732805"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>HER2-positive Breast Cancer</td>
    <td>Cancer Trials Ireland</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_84">Study Arms</button></td>
    <td><p>trastuzumab deruxtecan (T-DXd) (IV)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_553">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05710666" target="_blank">NCT05710666</a></td><td><select class="form-select" id="select_form_95" name="NCT05710666"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_83" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BCD-217 followed by prolgolimab 1 mg/kg monotherapy.|Prolgolimab monotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Placebo; Biological: BCD-100; Biological: BCD-217</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_84" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: trastuzumab deruxtecan (T-DXd) (IV)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The percentage of patients who achieve pCR after T-DXd treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of patients who achieve pCR after T-DXd treatment and thus avoid standard cytotoxic chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From registration until surgery approximately 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Enrollment increased by: 12; Primary Completion Date moved earlier by 1492 days</strong></td>
    <td>Metastatic/unresectable solid tumors or human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_85">Study Arms</button></td>
    <td><p>Entinostat; Ipilimumab; Nivolumab; Pharmacogenomic Study; Pharmacological Study</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_554">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02453620" target="_blank">NCT02453620</a></td><td><select class="form-select" id="select_form_96" name="NCT02453620"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 731 days; Trial terminated; Primary Completion Date moved earlier by 456 days</strong></td>
    <td>Fallopian Tube Cancer; Peritoneum Cancer; Epithelial Ovarian Cancer</td>
    <td>Marilyn Huang MD MS</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_86">Study Arms</button></td>
    <td><p>Pembrolizumab; Paclitaxel; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_554">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02834975" target="_blank">NCT02834975</a></td><td><select class="form-select" id="select_form_97" name="NCT02834975"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Trial completed</strong></td>
    <td>Covid19</td>
    <td>Thomas Jefferson University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_87">Study Arms</button></td>
    <td>Cytotoxic T Lymphocytes</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04765449" target="_blank">NCT04765449</a></td><td><select class="form-select" id="select_form_98" name="NCT04765449"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 16</strong></td>
    <td>Solid tumors</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_88">Study Arms</button></td>
    <td><p>Biopsy; Biospecimen Collection; Computed Tomography; Copanlisib; Ipilimumab; Magnetic Resonance Imaging; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_555">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03502733" target="_blank">NCT03502733</a></td><td><select class="form-select" id="select_form_99" name="NCT03502733"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date now March 20 2025</strong></td>
    <td>Recurrent/refractory Hodgkin Lymphoma</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_89">Study Arms</button></td>
    <td><p>Biopsy; Biospecimen Collection; Brentuximab Vedotin; Computed Tomography; Ipilimumab; Nivolumab; Positron Emission Tomography</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_555">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01896999" target="_blank">NCT01896999</a></td><td><select class="form-select" id="select_form_100" name="NCT01896999"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Enrollment increased by: 23</strong></td>
    <td>Recurrent grade II-III meningioma</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_90">Study Arms</button></td>
    <td><p>Biospecimen Collection; Echocardiography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Stereotactic Radiosurgery</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_555">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03604978" target="_blank">NCT03604978</a></td><td><select class="form-select" id="select_form_101" name="NCT03604978"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Changchun Intellicrown Pharmaceutical Co. LTD</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_91">Study Arms</button></td>
    <td>KN044</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04126590" target="_blank">NCT04126590</a></td><td><select class="form-select" id="select_form_102" name="NCT04126590"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Stevens-Johnson Syndrome; Toxic Epidermal Necrolyses</td>
    <td>Vanderbilt University Medical Center</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_92">Study Arms</button></td>
    <td><p>Harmonized supportive care; Cyclosporine 5 mg/kg bid days 0-14; Etanercept 50 mg sc day 0 and day 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_556">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02987257" target="_blank">NCT02987257</a></td><td><select class="form-select" id="select_form_103" name="NCT02987257"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 182 days</strong></td>
    <td>Newly diagnosed NK/T-cell lymphoma</td>
    <td>Won Seog Kim</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_93">Study Arms</button></td>
    <td>Tislelizumab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05477264" target="_blank">NCT05477264</a></td><td><select class="form-select" id="select_form_104" name="NCT05477264"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_85" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive entinostat PO on days -14 and -7 and then weekly nivolumab IV over 60 minutes on day 1 and then every 2 weeks and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Pharmacogenomic Study; Biological: Nivolumab; Biological: Ipilimumab; Other: Pharmacological Study; Drug: Entinostat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. Safety and tolerability will be analyzed through the incidence of adverse events serious adverse events and specific laboratory abnormalities (worst grade) in each arm. Toxicities will be tabulated by type and grade for all doses and presented using frequencies and percentages based on the CTCAE v5.0. The proportion of dose-limiting toxicities at each dose level will be reported with exact 95% confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 100 days after last dose of nivolumab</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_86" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:||Pembrolizumab 200mg intravenously (IV);|Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);|Paclitaxel same as NACT OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);|Carboplatin IV area under the curve (AUC) of 6.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Drug: Paclitaxel; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathologic Objective Response Rate (pORR) in Participants Receiving Protocol Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measure of pathologic response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 48 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_87" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; No Intervention</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells and then if there are no serious side effects the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested and each patient will complete a 14 day monitoring period before the next patient can be treated.|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure temperature and oxygen level (pulse oximetry) at home and report this information as well as their progress in getting over the COVID-19 infection to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cytotoxic T Lymphocytes</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of COVID-19-specific CTLs: Infusion Reactions|Safety of COVID-19-specific CTLs: Grade 4 AEs|Safety of COVID-19-specific CTLs: GVHD|Safety of COVID-19-specific CTLs: Marrow Aplasia|Safety of COVID-19-specific CTLs: Neurotoxicty|Safety of COVID-19-specific CTLs: CRS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be measured by the absence of: Grade ≥ 3 acute infusion reactions; Safety will be measured by the absence of: Any grade 4 or higher adverse event thought to be related to the CTL therapy and outside the spectrum of identified COVID related events.; Safety will be measured by the absence of: Any manifestation of acute GVHD (for acute grades 2-4 GVHD-Glucksberg criteria) 53 resistant to 2 mg/kg of solumedrol or equivalent; Safety will be measured by the absence of: Marrow aplasia due to 3rd party engraftment; Safety will be measured by the absence of: Grade ≥ 2+ Neurotoxicity as measured by the ASTCT/ICANS consensus grading system; Safety will be measured by the absence of: Grade ≥ 2+ CRS as measured by the ASTCT Consensus Grading Criteria for CRS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 14 days of CTL infusion; Within 48 Hours of CTL Infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_88" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive copanlisib IV over 1 hour on days 1 8 and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up as well as tumor biopsy on study.|Patients receive copanlisib IV over 1 hour on days 1 8 and 15 nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Beginning cycle 2 patients also receive ipilimumab IV over 90 minutes on day 1 for a total of 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up as well as tumor biopsy on study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Biopsy; Procedure: Computed Tomography; Biological: Nivolumab; Procedure: Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Biological: Ipilimumab; Drug: Copanlisib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Recommended phase 2 dose (RP2D) of copanlisib and nivolumab combination|Incidence of adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.; Will be defined as dose limiting toxicity in = 1 out of 6 patients at highest dose level below the maximally administered dose.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days after the last dose of study drug; Up to 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_89" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 8 12 and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 nivolumab IV over 30 minutes on day 1 of cycles 1-46 and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 nivolumab IV over 30 minutes on day 1 of cycles 1-34 and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Brentuximab Vedotin; Procedure: Biopsy; Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Biological: Ipilimumab; Biological: Nivolumab; Procedure: Biospecimen Collection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) of each combination (Phase I)|CR rate (Phase II)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The analysis of CR between two arms will be performed using exact Cochran-Mantel-Haenszel (CMH) test stratifying on prior brentuximab vedotin (BV) (yes versus [vs.] no) and age ( 18 vs. = 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.; MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Upon completion of the trial frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals (CI) around the toxicity proportions will be calculated.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days; Up to 10 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_90" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1 3 and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1 3 and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Stereotactic Radiosurgery; Procedure: Echocardiography; Biological: Nivolumab; Procedure: Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Biological: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated combination of radiosurgery and nivolumab plus or minus ipilimumab (Phase I)|Incidence of adverse event profile (Phase I)|Objective response rate (ORR) (Phase II)|Objective radiological response (Phase II)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will include either complete response or partial response as assessed on magnetic resonance imaging (MRI) per the modified Macdonald Criteria. 80% confidence intervals will be calculated.; Will be evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and percentage of subjects experiencing each type of adverse event will be tabulated by severity and relationship to treatment. If appropriate confidence intervals will be used to characterize the precision of the estimate. A complete listing of adverse events will also be tabulated and will provide details including severity relationship to treatment onset duration and outcome. Laboratory data measured on a continuous scale will be characterized by summary statistics (mean and standard deviation).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 100 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_91" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>KN044 0.03 mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 0.1 mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 0.3mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 1 mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 3 mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 6mg/kg dose grouponce every 3 weeks，a total of four cycles|KN044 10mg/kg dose grouponce every 3 weeks，a total of four cycles</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: KN044</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting toxicity for The maximum tolerated dose|KN044 of adverse event|KN044 of abnormalities of physical findings and laboratory tests</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose-limiting toxicity observation period 6 weeks after the first dose; The data of the clinical research center is collected and analyzed according to the time point of the test flow chart; the adverse events are recorded according to the actual occurrence</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>through study completion an average of 210 days; up to 6 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_92" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3|Harmonized supportive care with placebo etanercept days 0 and 3|Harmonized supportive care with placebo cyclosporine days 0-14</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Harmonized supportive care; Drug: Etanercept 50 mg sc day 0 and day 3; Drug: Cyclosporine 5 mg/kg bid days 0-14</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to complete re-epithelialization</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Patients will be assessed by two independent raters (burn surgeons dermatologists wound care experts) to determine the day of full re-epithelialization. For disagreements on the day of re-epithelialization the case with supporting photographs will be referred to an independent adjudication committee comprised of a minimum of three experts (a burn surgeon dermatologist wound care expert). In the instance of death will be the maximum period of re-epithelialization (21 days + 1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_93" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Induction therapy: Tislelizumab combined with radiation||Maintenance therapy(after termination of combination therapy)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tislelizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Complete response rate|Overall response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of subjects with complete response(CR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After induction therapy is completed Every 6 cycles of maintenance up to 51 months every 6month</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ia">New Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Kidney Transplant Infection; CMV</td>
    <td>University Hospital Rouen</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_94">Study Arms</button></td>
    <td><p>Belatacept</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_557">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05708534" target="_blank">NCT05708534</a></td><td><select class="form-select" id="select_form_105" name="NCT05708534"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_94" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To study the quantitative changes in anti-CMV T-lymphocyte immunity to the IE-1 antigen within 6 months of a switch from anticalcineurin treatment to belatacept in a cohort of kidney transplant recipients seropositive for CMV</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of interferon gamma-producing T lymphocytes in response to the IE-1 antigen determined by ELISPOT at M0 M3 and M6.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 731 days; Trial completed</strong></td>
    <td>Metastatic Cancer</td>
    <td>University of Erlangen-Nrnberg Medical School</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_95">Study Arms</button></td>
    <td><p>Nivolumab; Pembrolizumab; Radiotherapy; Ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_558">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03453892" target="_blank">NCT03453892</a></td><td><select class="form-select" id="select_form_106" name="NCT03453892"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Refractory Malignant Ascites</td>
    <td>Fudan University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_96">Study Arms</button></td>
    <td>Oncorine (H101)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04771676" target="_blank">NCT04771676</a></td><td><select class="form-select" id="select_form_107" name="NCT04771676"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Breast cancer or melanoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic)</td>
    <td>University of Southern California</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_97">Study Arms</button></td>
    <td>Anti-CD40 Agonist Monoclonal Antibody CDX-1140; Poly ICLC; Radiation Therapy; Recombinant Flt3 Ligand</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04616248" target="_blank">NCT04616248</a></td><td><select class="form-select" id="select_form_108" name="NCT04616248"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 334 days</strong></td>
    <td>Locally advanced or metastatic pancreatic cancer</td>
    <td>University of Virginia</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_98">Study Arms</button></td>
    <td>EGFR BATs after standard of care chemo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03269526" target="_blank">NCT03269526</a></td><td><select class="form-select" id="select_form_109" name="NCT03269526"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo9" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_95" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Radiation: Radiotherapy; Drug: Pembrolizumab; Drug: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Systemic (according to iRECIST criteria) and local response of detected metastases during radio and/or immunotherapy.|Change of circulating immune cells of treated patients by deep immunophenotyping.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Immunophenotyping of the patients: Detection of about 30 distinct immune sell (sub)types together with their activation markers. The analyses are conducted at time points before (day 0) and before every prescription of ICI (every 14 to 21 days) till progression or end of study at day 540.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From date of inclusion to the trial until the date of first documented iRECIST progression or date of death from any cause whichever came first assessed up to day 540.; The analyses are conducted at time points before (day 0) and before every prescription of ICI (every 14 to 21 days) till progression or end of study at day 540</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_96" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>H101 diluted in 5ml 0.9% sodium chloride solution will be intraperitoneally injected through the drainage catheter. Each patient will receive a dose of 1.5×10^12 vp by i.p. administration on day 1 and 3.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Oncorine (H101)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to repeat paracentesis (TTRP)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as the number of days between the first paracentesis (baseline) and the subsequent repeat paracentesis.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>max 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_97" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140; Drug: Poly ICLC; Radiation: Radiation Therapy; Biological: Recombinant Flt3 Ligand</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Maximum tolerated dose or maximum administered dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The dose limiting toxicity rate will be estimated by cohort and dose-level (if appropriate) using 90% confidence intervals obtained by Jeffrey's prior method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_98" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested armed with EGFR Biarmed activated T-cells washed to remove unbound EGFRBi and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: EGFR BATs after standard of care chemo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Overall survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An improvement in median overall survival (OS) defined as an increase from historical data of 8.7 months to 18.0 months.; Safety will be assessed by incidence and severity of adverse events changes in laboratory findings physical examinations vital signs and the number of dose limiting toxicities and other discontinuations due to adverse events.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Until subject's death or study closure (whichever occurs first) for an average of 36 months from study treatment completion; From the beginning of treatment (bridging chemotherapy) until no sooner than 30 days following the last study treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_500" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_501" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_502" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_504" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>TEMOZOLOMIDE</td>
          <td>TEMODAR</td>
          <td>MERCK SHARP DOHME</td>
          <td>['Aug 11 1999' 'Oct 19 2006' 'Feb 27 2009']</td>
          <td>['POWDER;INTRAVENOUS' 'CAPSULE;ORAL']</td>
          <td>['100MG' '140MG' '250MG' '100MG/VIAL' '180MG' '5MG' '20MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_507" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>MAGNESIUM SULFATE</td>
          <td>MAGNESIUM SULFATE</td>
          <td>FRESENIUS KABI USA</td>
          <td>['Jan 29 2016' 'Sep 8 1986']</td>
          <td>SOLUTION;INTRAMUSCULAR INTRAVENOUS</td>
          <td>['1GM/2ML (500MG/ML)' '5GM/10ML (500MG/ML)' '25GM/50ML (500MG/ML)' '10GM/20ML (500MG/ML)']</td>
            </tr>
            <tr>
          <td>MAGNESIUM SULFATE</td>
          <td>MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER</td>
          <td>HOSPIRA</td>
          <td>Jul 11 1995</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['1GM/100ML' '2GM/100ML']</td>
            </tr>
            <tr>
          <td>MAGNESIUM SULFATE</td>
          <td>MAGNESIUM SULFATE IN PLASTIC CONTAINER</td>
          <td>HOSPIRA</td>
          <td>['Jun 24 1994' 'Jan 26 2007' 'Jan 18 1995']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['4GM/50ML (80MG/ML)' '40GM/1000ML (40MG/ML)' '20GM/500ML (40MG/ML)' '2GM/50ML (40MG/ML)' '4GM/100ML (40MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>FLUOROURACIL</td>
          <td>ADRUCIL</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>CARAC</td>
          <td>VALEANT PHARMS NORTH</td>
          <td>Oct 27 2000</td>
          <td>CREAM;TOPICAL</td>
          <td>0.5%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>EFUDEX</td>
          <td>BAUSCH</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['CREAM;TOPICAL' 'SOLUTION;TOPICAL']</td>
          <td>['2%' '5%']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ALMIRALL</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>CREAM;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ELORAC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SOLUTION;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROURACIL</td>
          <td>SPECTRUM PHARMS</td>
          <td>['Approved Prior to Jan 1 1982' 'Jul 29 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2.5GM/50ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>TOLAK</td>
          <td>HILL DERMACEUTICALS</td>
          <td>Sep 18 2015</td>
          <td>CREAM;TOPICAL</td>
          <td>4%</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>ACCORD HLTHCARE</td>
          <td>Aug 3 2017</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/10ML (100MG/ML)' '1.5GM/15ML (100MG/ML)' '2GM/20ML (100MG/ML)' '200MG/2ML (100MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>HOSPIRA INC</td>
          <td>Aug 4 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2GM/52.6ML (38MG/ML)' '1GM/26.3ML (38MG/ML)' '200MG/5.26ML (38MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMZAR</td>
          <td>LILLY</td>
          <td>May 15 1996</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['EQ 200MG BASE/VIAL' 'EQ 1GM BASE/VIAL']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>INFUGEM</td>
          <td>SUN PHARM</td>
          <td>Jul 16 2018</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)' 'EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)' 'EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)' 'EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)' 'EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)' 'EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)' 'EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)' 'EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)' 'EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)' 'EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_510" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_512" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_515" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Amphadase</td>
          <td>Amphastar Pharmaceuticals Inc.</td>
          <td>10/26/2004</td>
          <td>Subcutaneous</td>
          <td>150UNITS/ML</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Hydase</td>
          <td>Akorn Inc.</td>
          <td>10/25/2005</td>
          <td>Subcutaneous</td>
          <td>150UNITS/ML</td>
            </tr>
            <tr>
          <td>hyaluronidase</td>
          <td>Vitrase</td>
          <td>Bausch & Lomb Incorporated</td>
          <td>['12/2/2004' '5/5/2004']</td>
          <td>Subcutaneous</td>
          <td>['6200UNITS/ML' '200UNITS/ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_517" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_519" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_521" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/VIAL' '80MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Jun 8 2011' 'Apr 20 2012']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/0.5ML (40MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Apr 12 2013' 'Sep 21 2015']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['140MG/7ML (20MG/ML)' '160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Mar 8 2011' 'Jun 23 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['120MG/6ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/16ML (10MG/ML)' '160MG/8ML (20MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/8ML (10MG/ML)' '130MG/13ML (10MG/ML)' '20MG/2ML (10MG/ML)' '200MG/20ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/8ML (10MG/ML)' '160MG/16ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['May 14 1996' 'Aug 2 2010' 'Apr 13 2012' 'Aug 3 2010']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_526" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_527" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>trastuzumab</td>
          <td>Herceptin</td>
          <td>Genentech Inc.</td>
          <td>['9/25/1998' '2/10/2017']</td>
          <td>Intravenous</td>
          <td>['420MG' '150MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_528" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_530" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_536" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_538" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_539" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_541" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_543" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/VIAL' '80MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Jun 8 2011' 'Apr 20 2012']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)' '80MG/2ML (40MG/ML)' '20MG/0.5ML (40MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Apr 12 2013' 'Sep 21 2015']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['140MG/7ML (20MG/ML)' '160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Mar 8 2011' 'Jun 23 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['120MG/6ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/16ML (10MG/ML)' '160MG/8ML (20MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/8ML (10MG/ML)' '130MG/13ML (10MG/ML)' '20MG/2ML (10MG/ML)' '200MG/20ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/8ML (10MG/ML)' '160MG/16ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['May 14 1996' 'Aug 2 2010' 'Apr 13 2012' 'Aug 3 2010']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_546" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_552" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_553" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>trastuzumab</td>
          <td>Herceptin</td>
          <td>Genentech Inc.</td>
          <td>['9/25/1998' '2/10/2017']</td>
          <td>Intravenous</td>
          <td>['420MG' '150MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_554" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_555" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_556" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>CEQUA</td>
          <td>SUN PHARM</td>
          <td>Aug 14 2018</td>
          <td>SOLUTION;OPHTHALMIC</td>
          <td>0.09%</td>
            </tr>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>NEORAL</td>
          <td>NOVARTIS</td>
          <td>Jul 14 1995</td>
          <td>['CAPSULE;ORAL' 'SOLUTION;ORAL']</td>
          <td>['50MG' '100MG' '25MG' '100MG/ML']</td>
            </tr>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>RESTASIS</td>
          <td>ALLERGAN</td>
          <td>Dec 23 2002</td>
          <td>EMULSION;OPHTHALMIC</td>
          <td>0.05%</td>
            </tr>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>RESTASIS MULTIDOSE</td>
          <td>ALLERGAN</td>
          <td>Oct 27 2016</td>
          <td>EMULSION;OPHTHALMIC</td>
          <td>0.05%</td>
            </tr>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>SANDIMMUNE</td>
          <td>NOVARTIS</td>
          <td>['Mar 2 1990' 'Nov 14 1983' 'Nov 23 1992']</td>
          <td>['INJECTABLE;INJECTION' 'CAPSULE;ORAL' 'SOLUTION;ORAL']</td>
          <td>['100MG' '100MG/ML' '50MG/ML' '50MG' '25MG']</td>
            </tr>
            <tr>
          <td>CYCLOSPORINE</td>
          <td>VERKAZIA</td>
          <td>SANTEN</td>
          <td>Jun 23 2021</td>
          <td>EMULSION;OPHTHALMIC</td>
          <td>0.1%</td>
            </tr>
            <tr>
          <td>etanercept</td>
          <td>Enbrel</td>
          <td>Immunex Corporation</td>
          <td>[nan '11/2/1998' '3/5/2020' '5/27/1999' '2/1/2007' '9/27/2004']</td>
          <td>Subcutaneous</td>
          <td>['50MG/ML' '25MG/0.5ML' '25MG']</td>
            </tr>
            <tr>
          <td>etanercept</td>
          <td>Enbrel Mini</td>
          <td>Immunex Corporation</td>
          <td>9/14/2017</td>
          <td>Subcutaneous</td>
          <td>50MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_557" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>belatacept</td>
          <td>Nulojix</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>6/15/2011</td>
          <td>Intravenous</td>
          <td>250MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_558" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '100MG/10ML' '120MG/12ML']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
